Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors

Advanced/Metastatic Solid Tumors Clinical Trial

Official title:
An Open-Label, Multicenter, Dose Escalation Phase Ib Study With Expansion Cohorts to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Therapeutic Activity of RO7009789 (CD40 Agonistic Monoclonal Antibody) in Combination With Vanucizumab (Anti-Ang2 and Anti-VEGF Bi-Specific Monoclonal Antibody, Part I) or Bevacizumab (Anti-VEGF Monoclonal Antibody, Part II) in Patients With Metastatic Solid Tumors

Status Completed

Clinical Trial Summary

This open-label, two-part study is designed to assess the safety, PK, PD, and therapeutic activity of Selicrelumab in combination with vanucizumab or bevacizumab in participants with metastatic solid tumors not amenable to standard treatment. Part I (dose escalation) is designed to establish the maximum tolerated dose (MTD) of Selicrelumab in this combination. Part II (expansion) is intended to characterize the safety and tolerability of Selicrelumab in combination with bevacizumab among indication-specific cohorts and to confirm the recommended dose.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02665416
Study type	Interventional
Source	Hoffmann-La Roche
Contact
Status	Completed
Phase	Phase 1
Start date	January 25, 2016
Completion date	October 30, 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05514444` - Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)	Phase 1
Active, not recruiting	`NCT04501276` - A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients	Phase 1
Active, not recruiting	`NCT04182516` - Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors	Phase 1
Terminated	`NCT00996255` - Dose-Escalation Study of PHA-793887 in Patients With Advanced/Metastatic Solid Tumors	Phase 1
Terminated	`NCT02444793` - A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors	Phase 1
Recruiting	`NCT03526835` - A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT05718895` - A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors	Phase 1
Completed	`NCT03833427` - Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)	Phase 1
Recruiting	`NCT04645069` - ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT05607498` - First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma	Phase 1
Recruiting	`NCT05405595` - ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors	Phase 1/Phase 2
Terminated	`NCT01092052` - Study of NMS-1116354 in Advanced/Metastatic Solid Tumors	Phase 1
Completed	`NCT05277402` - ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors	Phase 1
Recruiting	`NCT05614258` - Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors	Phase 1
Active, not recruiting	`NCT05394168` - A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors	Phase 1